The past 18 months have been absolutely terrible for Novo Nordisk (NYSE: NVO). The Denmark-based drugmaker has faced poor ...

Researchers adjusted for confounders like age, hypertension, cardiovascular disease, and other comorbidities. The refined results indicated GLP-1 users had a 16% lower risk of developing epilepsy ...

Global diabetes drug Ozempic (semaglutide) has now been launched in India by Danish pharmaceutical major Novo Nordisk. In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...

Ozempic (injectable semaglutide) is a once-weekly treatment indicated as an add-on to diet and exercise for adults with ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...

Danish pharmaceutical giant Novo Nordisk has introduced its type 2 diabetes treatment, Ozempic, in India. Positioned as a ...

Dozens of units of counterfeit Ozempic (semaglutide 1mg injection) were seized by the FDA, according to a drug safety alert issued by the Agency.

FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from ...

Novo Nordisk launches Ozempic in India, outlining prices, doses, and its bid to capture rising diabetes and weight-loss ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...